Peer review reports
From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
Original Submission | ||
---|---|---|
3 Apr 2021 | Submitted | Original manuscript |
15 Apr 2021 | Reviewed | Reviewer Report |
18 Apr 2021 | Reviewed | Reviewer Report |
28 Apr 2021 | Reviewed | Reviewer Report |
6 May 2021 | Author responded | Author comments - Minshan Chen |
Resubmission - Version 2 | ||
6 May 2021 | Submitted | Manuscript version 2 |
6 May 2021 | Author responded | Author comments - Minshan Chen |
Resubmission - Version 3 | ||
6 May 2021 | Submitted | Manuscript version 3 |
7 May 2021 | Author responded | Author comments - Minshan Chen |
Resubmission - Version 4 | ||
7 May 2021 | Submitted | Manuscript version 4 |
8 May 2021 | Reviewed | Reviewer Report |
9 May 2021 | Reviewed | Reviewer Report |
23 May 2021 | Reviewed | Reviewer Report |
25 May 2021 | Author responded | Author comments - Minshan Chen |
Resubmission - Version 5 | ||
25 May 2021 | Submitted | Manuscript version 5 |
27 May 2021 | Reviewed | Reviewer Report |
27 May 2021 | Reviewed | Reviewer Report |
Resubmission - Version 6 | ||
Submitted | Manuscript version 6 | |
Publishing | ||
27 May 2021 | Editorially accepted | |
4 Jul 2021 | Article published | 10.1186/s12885-021-08428-w |